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Urothelial carcinoma of the urinary bladder (UCB) or bladder cancer remains a major
health problem with high morbidity and mortality rates, especially in the western world.
UCB is also associated with the highest cost per patient. In recent years numerous
markers have been evaluated for suitability in UCB detection and surveillance. However,
to date none of these markers can replace or even reduce the use of routine tools
(cytology and cystoscopy). Our current study described UCB’s extensive expression
profile and highlighted the variations with normal bladder tissue. Our data revealed
that JUP, PTGDR, KLRF1, MT-TC, and RNU6-135P are associated with prognosis in
patients with UCB. The microarray expression data identified also S100A12, S100A8,
and NAMPT as potential UCB biomarkers. Pathway analysis revealed that natural killer
cell mediated cytotoxicity is the most involved pathway. Our analysis showed that
S100A12 proteinmay be useful as a biomarker for early UCB detection. Plasma S100A12
has been observed in patients with UCB with an overall sensitivity of 90.5% and a
specificity of 75%. S100A12 is highly expressed preferably in high-grade and high-stage
UCB. Furthermore, using a panel of more than hundred urine samples, a prototype lateral
flow test for the transcription factor Engrailed-2 (EN2) also showed reasonable sensitivity
(85%) and specificity (71%). Such findings provide confidence to further improve and
refine the EN2 rapid test for use in clinical practice. In conclusion, S100A12 and EN2
have shown potential value as biomarker candidates for UCB patients. These results
can speed up the discovery of biomarkers, improving diagnostic accuracy and may help
the management of UCB.
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INTRODUCTION
Bladder cancer (- urothelial carcinoma of the urinary bladder,
UCB) is the fourth and ninth most common cancer in men and
women, respectively (1, 2). The global prevalence of UCB in
Europe and North America has been estimated at 2.7 million (1,
2). UCB leads to significant mortality, with a survival rate of just
47–57% when linked to muscle-invasive disease (3). In addition
to its effect on UCB patients, the disease poses a significant
economic burden on healthcare systems with a mean treatment
and monitoring cost of ∼200,000 USD per patient, rendering it
the most expensive of all tumors to treat (4).
Generally, after haematuria, most patients experience a similar
clinical process (5, 6). There were also several biomarkers used for
diagnostic and monitoring purposes, but no marker has yet been
shown to reduce the need for cystoscopy (6–11). This is especially
problematic given the high recurrence rate, because of which
lifelong surveillance is needed to detect any recurrence as early
as possible (10). The development of reliable, non-invasive tests
could therefore improve not only the UCB diagnosis itself but
also the quality of life for patients with a disease history, and in
this regard the detection of biomarkers in bodily fluids has shown
a high potential (4–8, 10). TheUS Food andDrug Administration
(FDA) has approved only a few urine-based tests, and there are
currently no blood based tests (6, 10). Therefore, more novel
biomarkers are urgently needed to detect UCB in general and
especially in high-risk populations where the disease prevalence
appears to be high (12, 13). The transcription factor Engrailed-
2 (EN2) was previously shown to be a specific and potentially
sensitive marker for bladder and prostate cancer (14–20). Using a
standard ELISA method, we have previously shown that urinary
EN2 could be detected and used as a UCB diagnosis biomarker,
even in the early and non-invasive stages of the disease (15).
In addition to EN2, we have also investigated the diagnostic
potential of S100 protein family members. The S100 family
consists of 25 members, the expression of which have only been
described in vertebrates (21). These proteins are characterized
by a low molecular weight (9–13 kDa) and two Ca2+ binding
sites in the form of EF-hands, one of which is unconventional
(N-terminal) and has 100 times higher Ca2+ affinity than
the canonical binding site in C-terminal. The S100 family
members differ in length and sequence of the hinge region
between the binding sites as well as the extension at C-
terminal following the C-terminal EF-hand (22). The functions
of S100 Proteins range from controlling protein phosphorylation,
enzyme activity and transcription factors over the dynamics of
cytoskeleton constituents, Ca2+ homeostasis and cell growth,
and differentiation to an involvement in the inflammatory
response (22, 23). They also mediate proinflammatory activity
through binding the receptor for advanced glycation end-
products (RAGE) on endothelial cells as well as recruitment of
monocytes (23–27). Among the S100 group, S100A12, and S100P
are unusual in that the coding gene can be found in the human
genome but not in the mouse genome (28–30). S100A12 was
recently shown to bind to CD36, a class B scavenger receptor, and
this binding mediated translocation of CD36 to the membrane
and where it can regulate lipid transport by direct interaction
(31). Altered S100 protein levels have been linked to a variety of
diseases, including cancer, neurodegenerative disorders, immune
disorders, and inflammatory conditions (29). S100 genes also
were shown to have roles in UCB progression and tumorigenesis
(32). S100A8 and S100A9 were found to be increased in UCB
patients and their expression related to stage and grade of the
tumor (33). S100A12 RNA expression was shown to be increased
in the tumors of transitional cell carcinoma (TCC) patients (34),
and another study found that the urinary canine S100A8/A9
concentration relative ratio to S100A12 concentration maybe
useful as a marker for canine TCC (35).
The main aim of this study was to assess the changes in blood
gene expression in UCB patients and to identify genes serving
as biomarkers for UCB diagnosis and progression. We identified
elevated expression of the human S100A12 as a bladder cancer-
enriched gene that is potentially a sensitive and specific diagnostic
biomarker for UCB. Motivated by the fact that there is rapid
growth in the demand for point-of-care tests based on lateral
flow assays with high sensitivity, specificity and low cost, we
also developed a lateral flow rapid test for detection of EN2 in
urine samples. More than one hundred clinical samples were
used to validate the rapid test which exhibited high sensitivity
and specificity.
MATERIALS AND METHODS
Ethics Statement
All patients and healthy volunteers participating in the study gave
written informed consent for sample donation and the collection.
The protocol was approved by the local ethical committee of
Faculty of Health and Medical Sciences, University of Surrey
(Ref. 3/LO/0739).
Specimen, Data Collection, and Study
Design
Patients selection was based on the following inclusion criteria:
the patient was diagnosed with urothelial carcinoma of the
urinary bladder (cystoscopic and histological evidence of Bladder
Cancer). Recurrence-negative patients during monitoring have
been defined as showing no cystoscopic or histological
evidence of bladder cancer. Recurrence-positive patients during
monitoring after treatment for de novo bladder cancer are
identified as showing cystoscopic and histological evidence of
bladder cancer. New patients were patients with bladder cancer
without a history of UCB. Healthy volunteers had no previous
history of bladder cancer or any other cancer (Table 1). The
average age of positive cancer patients was 75.4 years and the
average age of recurrence-negative patients was 70.5 years. The
average age of new bladder cancer patients was 76.7 years and
the average age of healthy volunteers was 68 years. Plasma from
blood samples was collected from the same cohort of patients
except 4 patients and one healthy volunteer were missed. Plasma
was obtained using BD Vacutainer R© Plasma Tubes (Heparin).
Tubes containing 8–10mL of blood were mixed for 30min at
RT and centrifuged at 1,600 g for 10min at RT. Plasma was
added to a fresh tube and centrifuged again at 1400 g for 10min
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TABLE 1 | Participant and specimen characteristics summary for microarray and plasma.
No of TCC patient (transitional cell (urothelial) carcinoma) Muscle
invasive
Patients No of patients Total No of TCC
patient
G 1 pTa G 2
pTa
G 2
pT1
G3 pTa G3 T1 G3 T2a
Risk group Low risk Intermediate
risk
Intermediate
risk
High risk High risk High risk
Recurrence-positive 17 15 4 9 1 0 1 2
Recurrence-negative 18 0 0 0 0 0 0 0
New Bladder Cancer patients 11 9 1 4 3 0 1 2
Health volunteers 29 0 0 0 0 0 0 0
FIGURE 1 | Workflow scheme. From the blood samples, the total RNA was first isolated, subjected to a quality control, and converted to cDNA. Subsequently, after
hybridization, labeling, and scanning of the microarray’s chips were done. Data analysis in relation to the status of the disease, the risk group and the prognosis of the
patients performed with two programs Partek® and ArrayStar®. From the differentially expressed genes the potential markers and verified their expression with a
qPCR.
at RT. Plasma was then transferred to cryo-vials and stored
at −80◦C. Whole blood was collected using BD PAXgeneTM
Blood RNA Tubes. After the patient was bled the PAXgeneTM
Blood RNA Tubes were incubated at RT for 2 h and then chilled
on ice for 10min. The tubes were then incubated at −20◦C
overnight and then transferred to a storage box at −80◦C. The
workflow of the current microarray study from blood samples
is illustrated in Figure 1. For EN2 detection using the lateral
flow test, 62 urine samples from positive patients with cystoscopy
and histological evidence of bladder cancer were used. This
group in second analysis was grouped to different stages (Ta
= 35 samples, T1 = 7, and T2-T3 = 9) and grades (36–38)
(G1 = 11, G2 = 33, and G3 = 17) to evaluate the clinical
sensitivity of the rapid test by tumor stage and grade. It was
not possible to determine a stage (I) or a grade (II) for only
one specimen. Forty-six negative samples were collected from
healthy volunteers without any previous history and symptoms of
bladder cancer or any other cancer. All urine samples were stored
at−20◦C.
RNA and Array Processing
Isolation of total RNA from clinical whole blood samples
was performed according to the protocol of the manufacturer
using the PAXgene R© Blood RNA-Kit (PreAnalytiX). The total
RNA was quantified by a QubitTM Assay (Invitrogen) based
on the manufacturer’s standard protocols. The RNA integrity
was determined by agarose gel electrophoresis. Using the
manufacturer’s protocol, the RNA samples were processed by
the GeneChip R© WT Plus Reagent Kit (Affymetrix). In summary,
the total RNA firstly transcribed to double stranded cDNA, then
transcribed to cRNA. The cRNA was then synthesized into single
stranded cDNA, and then fragmented and biotinylated. Finally,
the biotinylated single stranded cDNA has been hybridized onto
the whole transcript Affymetrix R© Human Gene 2.1 ST arrays,
which cover a total of 40.716 annotated transcripts. The strips
were then labeled using a streptavidin phycoerythrin conjugate,
washed and scanned using the GeneAtlas R© System (Affymetrix).
Using the Command ConsoleTM software (Affymetrix), the probe
cell intensity data (CEL) files were created.
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Gene and Exon Expression Analysis
For the gene and exon expression analysis, the CEL files
are imported into Partek Genomics Suite version 6.6 (Partek
Inc., St. Louis, MO, USA) and normalized using the Robust
Multi-array Average (RMA) settings. A batch effects removal
was performed to minimize the influence of external factors
on the data using the tool in Partek software. The lists of
differentially expressed genes were created using analysis of
variance (ANOVA) with an fdr (false discovery rate) corrected
p <0.05 and a fold change >1.5 (39–42). The QC metrics
table and QC graphical report was used to assess of the quality
the experiments. The average linkage hierarchical clustering
was conducted using spearman’s correlation as a similarity
matrix. Using the Partek Gene Ontology (GO) Enrichment
tool, differentially expressed genes were grouped into functional
categories ranked according to their p-values. Additionally, the
differentially expressed genes were plotted in a volcano plot.
The differentially expressed genes filter according to their fold-
change were used for further functions analysis using Pathway
analysis utilizing KEGG database (Partek R© PathwayTM). The
significantly enriched pathways (using a Fisher’s exact test) were
determined and visualized by Partek Pathway. Enrichment Score
(Fisher’s Exact test) was used to sort the top enriched pathways
out of differentially expressed genes). In the second analysis the
CEL file were imported into DNASTAR R© ArrayStar R© (version
12.0) software (DNASTAR. Madison, WI) using again the RMA
normalization. The lists of differentially expressed genes were
generated using a Student’s t-Test with a confidence interval
>95% and a fold chance >1.5. Differentially expressed genes
were grouped into their functional categories ranked according
to their p-values using the Gene Ontology (GO) Enrichment
tool. Unannotated and duplicate probe sets were removed from
the lists.
Quantitative Real-Time PCR (qPCR)
Expression of selected genes was verified performing a
quantitative PCR (qPCR) using the housekeeping gene GAPDH
as reference. The primers used are described in Table S1. The
analysis was performed in 20 µL containing each 10 µL 2x
FastStart Essential DNA Master Mix (Roche), 2.4 µL H2O (PCR
grade), 1.3 µL from 8µM of the respective forward and reverse
primers and 5 µL from 5 ng/µL template DNA. As template
DNA the single strand cDNA generated for the microarrays was
used. No template was included in the negative control. The
following steps were included in the PCR Protocol: denaturation
at 95◦C followed by 9 touch-down cycles with the annealing
temperature decreasing 1◦C per cycle from 61◦ to 53◦C. Then 31
cycles followed with 20 s at 95◦C, 20 s at 53◦C, and 20 s at 72◦C.
Finally, the DNA was denatured at 95◦C for 20 s then at 55◦C
for 60 s and at 97◦C for 1 s to generate the melting curves. The
qPCR was performed on the Light Cycler R© 96 (Roche) and the
relative gene expression was determined using the Light Cycler R©
96 software (version 1.1). Normalization was performed using
the healthy samples as run calibrator. The normalized ratios
were calculated as the ratio of the samples (target/reference)
divided by the ratio of run calibrator (target/reference) using
healthy samples.
Recombinant S100A12 Synthesis
The target gene was amplified using plasmid pENTR223.1
containing cDNA fragment of human S100A12 (Hölzel
Diagnostika, Germany) as template and primers with the
5′-3′-sequences CGCGCGCCATGGTTACAAAACTTGAAGA
GCATC and CGCGCGAAGCTTACTCTTTGTGGGTGTG
GTAA, respectively. The ends of the PCR product were cleaved
using FastDigest restriction endonucleases NcoI and HindIII
(Thermo Scientific). By ligation to IPTG-inducible expression
vector pLEXWO481 digested before with the same enzymes
set the S100A12 reading frame was fused in frame with the
N-terminal His-tag. E. coli DH5α (NEB) was transformed using
ligationmixture. Afterwards plasmids were isolated from positive
transformants and confirmed by sequencing. For production of
biomass of recombinant E. coli DH5α cells we used previously
described conditions (43).
Purification of His-Tagged Recombinant
S100A12
All of the following purification steps were performed on ice or
at 4◦C. A cell pellet of 9.6 g in weight was thawed on ice and
suspended in 20mM Tris-HCl, 100mM NaCl, pH 8.0 for 0.1
grams of cell pellet per mL. The cells were agitated gently for
∼1 h and homogenized (Miccra D-8). Cell lysis was performed
by sonication (Bandelin Sonopuls GM 70, equipped with a UW
70 booster horn). Sonication was performed on ice for 5 × 30
sec. min. at 80% amplitude, with breaks between cycles to prevent
warming of the mixture. The lysate was centrifuged at 27,000× g,
8◦C for 30min to remove unlysed cells and insoluble cell debris.
The supernatant (cleared lysate) was filtered through a fluted
filter and the pellet was discarded. The following Ni-NTA affinity
chromatography and gel filtration was performed with an Äkta
prime plus chromatography system (GEHealthcare). The cleared
lysate was applied on a column (HiScale 16, GE Healthcare)
containing 5mL Ni-NTA superflow resin that had been pre-
equilibrated in 20mM Tris-HCl, 100mM NaCl, pH 8.0. After
washing the column with 5 column volumes of 20mM Tris-HCl,
100mMNaCl, pH 8.0, a linear imidazole gradient from 0 to 1.0M
was applied over 20 column volumes. 2.5-mL fractions were
collected over the gradient. The recombinant S100A12 protein
was eluted with approximately 250mM imidazole. Fractions
containing S100A12 with a purity of 95% or higher were
pooled. Buffer exchange against 10mM NH4HCO3, pH 8.0 was
performed using a prepacked desalting HiScale 16 column, filled
with 40mL Sephadex G-25 Medium (GE Healthcare). Protein-
containing fractions were pooled and filtered through a 0.2µM
PES filter (Millex-GP, Merck Millipore).
Immunohistochemistry
The tissue array (Biomax BL802a), was subjected to
deparaffinization in a series of alcohols and antigen retrieval in
boiling in 0.01M citrate buffer. Slides were blocked in normal
horse serum (Vector Laboratories, UK) and Avidin/Biotin
blocking kit (Vector Laboratories, UK). Sections were incubated
with 1:1,000 S100A12 primary antibody (Sigma HPA002881)
or PBS/0.1% BSA (negative control), before adding universal
secondary antibody (Vector Laboratories, UK). ABC reagent
(Vector Laboratories, UK) was dropped onto sections, followed
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by DAB substrate solution (Vector Laboratories, UK). Sections
were counterstained with haematoxylin (Vector Laboratories,
UK), before being dehydrated in a series of alcohols, cover
slipped with Vector mounting media (Vector Laboratories, UK),
and visualized by light microscopy.
S100A12 Quantitation in Plasma Samples
Using Biolayer Interferometry (BLI)
BLI experiments were conducted using an Octet QKe Instrument
and high precision streptavidin biosensor (SAX), manufactured
by ForteBio (Menlo Park, CA, USA). By measuring the light
interference on the fiber optic sensor surface, and this is directly
proportional to the thickness of the surface-bound molecules.
Antibodies against S100A12 are chemically attached to the
sensor surface using biotin-streptavidin interactions. Binding
of S100A12 in the diluted plasma to the tethered antibodies
results in surface thickening, which is monitored in real time.
Purified rabbit anti-S100A12 polyclonal IgG were obtained from
St. John’s Laboratory (London, UK). Anti-S100A12 antibodies
were biotinylated using Biotin Protein Labeling Kit (Roche) per
the manufacturer’s instructions. Sephadex G-25 columns (GE
Healthcare) were then used to remove unreacted biotinylation
reagent and buffer exchange into PBS. The biotinylated anti-
S100A12 was immobilized on SAX biosensors at a single
concentration of 10µg/mL for 40min (online). A solution of
0.1% BSA in PBS was used as blocking agent for 5min to reduce
the impact of non-specific binding to the surface of the sensor
the sensors. The regeneration of the sensors was performed
with 10mM glycine buffer (pH = 2.2). All experiments were
performed at 30◦C with an agitation set at 1,000 rpm using solid
black 96-well plates (Greiner Bio-One) with 10min assay time
(read time window) of dipping the prepared sensors in each well.
The final volume for all the solutions was 200 µL/well. Different
concentrations of recombinant S100A12 (from 1,857 ng/mL to
0µg/mL) spiked in 1:12 diluted healthy human plasma to
stablish the standard curve. The cohort plasma samples were
all 1:12 diluted using PBS, pH 7.4 before applying in the
assay plate. Data were analyzed with the Octet System Data
Analysis software v7.1 (ForteBio, Menlo Park, CA, USA), and the
S100A12 concentration in plasma samples was obtained using
calibration curve which set up using the BLI response (binding
rate) to the spiked rS100A12 concentration. Statistical analysis
was performed using the GraphPad prism package. Unpaired t-
test with Welch’s correction was used to test the significance of
differences between mean S100A12 concentrations in different
patient groups. Receiver operator characteristics (ROC) curves
were generated for the S100A12 and the unpaired t-test was used
to test the area under the curve for significance. A combinatorial
analysis of both S100A12 and EN2 as combi-biomarker and
receiver operating characteristic (ROC) curve was carried out to
using the CombiROC method (http://CombiROC.eu) (44).
Lateral Flow Prototype Development to
Detect EN2 in Urine
The EN2 detection test is a membrane-based test for the
qualitative detection of EN2 protein in urine through visual
interpretation of color development in the test device. The
test is based on the principle of Competitive Enzyme Immune
Assay with a single test strip contained within a test cassette.
This test strip consists of a proprietary EN2-binding IgG
antibody (LIONEX GmbH) coupled to a colored conjugate, and
a membrane with one test line and one control line. The test
line contains EN2 recombinant protein (LIONEX GmbH), the
control line consists of an antibody-binding protein (Rabbit
anti mouse IgG, Thermo Scientific Fischer). The urine sample
(60 µL) is pipetted into the sample well (S) followed by the
diluent buffer (60 µL) 1min later, the diluted sample passes
through the conjugate and the EN2 protein in the sample binds
to the conjugate. The EN2-conjugate complex migrates due to
the capillary action to the site of the membrane where the
recombinant EN2 protein is immobilized (test line) and the
competition will take place between the sample EN2 and the
coated EN2 on the membrane to the colored particle-labeled
specific EN2 antibodies. If EN2 is absent or at a low concentration
in the sample the labeled anti-EN2 attaches to the coated EN2 on
themembrane and color intensity increases. If a high level of EN2
is in the sample, the EN2 is captured by the labeled anti-EN2 and
the complex migrates through the membrane without attaching
to the EN2 already coated on the test-region. In consequence the
color of the test line appears weaker or no test line appears. The
remaining complex migrates further across the membrane to the
control zone (“C”). Again, a colored line appears, indicating that
the test was performed correctly. After 15min the intensity in the
test line is compared to the Reference Scale card (Figure S1). For
a positive result two colored lines appear in “T” and “C” or only
one colored line appears in the control zone “C.” The test line “T”
can be absent or appears weak. The test will be considered as a
negative result when two colored lines appear in “T” and “C”; the
test line “T” appears strong. The test result is considered invalid
if only the test line appears. The control line plays the role of
an internal positive control for the lateral flow test and indicates
successful test flow.
RESULTS
Gene Expression Analysis of UCB Patients
We carried out blood sample gene expression profiling in UCB
cancer patient groups and/or in comparison to the healthy
samples (Table 1). Comparing the expression profiles revealed
a set of 14 differentially regulated genes. Of these, 5 were
upregulated in bladder cancer while 9 were downregulated
(Figure 2). The significance of regulated genes was set based
on an fdr-corrected p- <0.05 and a fold change >1.5.
This criterion was chosen to allow differentially expressed
genes to simultaneously meet both fdr-controlled p-value and
fold-change requirements even with arbitrarily small fold-
changes (45–47). The most significantly upregulated genes
included RNASE2, RNU6-237P, and S100A12, while the most
significantly downregulated genes comprised IGLV3-21, IGHV1-
2, and TRAV13-1.
Next, the UCB cohort patient samples were divided into
different groups according to the prognosis of the patients. New
UCB cases were labeled “new positive,” in case of a recurrence
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FIGURE 2 | Volcano plot of differentially expressed genes in UCB patients against probability. The figure shows data points of only differentially expressed genes lying
above the fold change >1.5 and fdr-corrected p <0.05. Points to the right (red) represent candidates that were upregulated in UCB, while points to the left (blue)
were downregulated.
of the disease within 5 years after treatment the samples were
assigned to the group “recurrent” and patients with a bladder
cancer history but negative at the time the sample was taken
were placed in the “previously positive” group. The analysis of
variance (ANOVA) was carried out between these groups and
revealed a total of 127 differentially regulated genes (Figure 3).
The comparison between the new positive samples and the
negative control samples accounted for most of these genes
showing 9 upregulated genes among the new positive patients
and 38 downregulated genes. In total the comparison between the
recurrent and the new positive samples revealed 38 differentially
regulated genes. As shown in Figure 3, 18 of these genes were
exclusively found in this comparison as possible prognostic
markers to distinguish recurrent cases from new UCB cases
(Table S2).
To identify a pattern of expression associated with UCB
recurrence, we noticed that PTGDR, KLRF1 and MT-TC genes
were found to be significantly downregulated in new positive
samples compared to negative and recurrent samples, while
RNU6-135P was upregulated in new positive samples compared
to previously positive and recurrent samples (Table 2). To further
investigate the effects of risks groups in UCB, a model was built
using healthy, previously positive patients and dividing samples
into risk groups according to stage and grade of the disease as
defined previously (48) (Table 1). ANOVA analysis carried out
between these groups revealed no differentially regulated genes
in the comparison between the low risk and negative samples.
When comparing high risk and negative controls only the JUP
gene was found to be significantly upregulated (fdr-corrected p
<0.05; fold change >1.5) (Table S3), whilst a comparison of the
intermediate risk group and negative controls revealed a total of
20 differentially regulated genes, 4 of which were upregulated
while 16 were downregulated in the intermediate risk group.
The most significantly upregulated genes were RNU6-707P and
S100A12. TRAJ29 and TRAJ17 were the most significantly
downregulated genes (Table S3).
Significantly enriched pathways are shown in Table 3 from
the Partek pathway analysis of UCB patients vs. healthy group
sorted by the Enrichment Score (Fisher’s exact test). This analysis
showed that the genes significantly affected by bladder cancer are
involved in the antigen processing and presentation, natural killer
cell mediated cytotoxicity, and the ubiquitinmediated proteolysis
pathways. By analyzing different combinations of the expression
data in the prognostic and risk groups, the comparisons showed
regulation in several pathways. It was noticeable, however, that
the natural killer cell mediated cytotoxicity pathway repeatedly
appeared in comparisons of different patient groups against the
healthy and within the prognostic/risk groups (Table 4).
S100A12 Is UCB Relevant and Its
Expression Is Elevated in High-Risk
Patients
S100A12 was the only gene which was found to be differentially
regulated in several analyses. This gene was significantly
upregulated in the comparisons between patients and healthy
volunteers as well as between intermediate risk patients and
healthy volunteers. In both cases a fold change of 1.6 was
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FIGURE 3 | Venn diagram shows the comparison and overlapping of regulated genes in different comparison of UCB according to their prognostic’s groups.
Significance was selected based on a fold change >1.5 with fdr-corrected p <0.05.
TABLE 2 | Selected potential prognostics biomarkers.
Gene Fold change
New positive
vs. Healthy
Recurrent vs.
New positive
New positive vs.
Previously positive
KLRF1 (Killer cell
lectin-like receptor
subfamily F member 1)
−1.87 1.97 −1.57
PTGDR (Prostaglandin
D2 receptor)
−1.71 1.73 –
MT-TC (Mitochondrially
encoded tRNA cysteine)
−1.91 2.04 −1.80
RNU6-135P (RNA, U6
small nuclear 135,
pseudogene)
– −2.65 1.98
associated to this gene. In order to detect potential biomarkers,
these results were checked by analyzing again the microarray
raw data using DNAStar ArrayStar software. A student’s t-test
was applied with a confidence interval of 95% and a fold change
>1.5. We identified a total of 141 differentially regulated genes,
all of which were upregulated in UCB patients (Table S4). The
topGO functions for disease effects were heavily weighted toward
immune system process, regulation, inflammatory response,
cellular homeostasis, and cell cycle genes. The list of the cellular
homeostasis and cell cycle genes out of GO enrichment clustering
TABLE 3 | The selected top pathways.
Pathway name Database Enrichment
score
Enrichment
p-value
Antigen processing and presentation kegg 3.88856 0.0204748
Natural killer cell mediated cytotoxicity kegg 3.29709 0.0369907
Ubiquitin mediated proteolysis kegg 3.22929 0.0395856
The analysis done using Partek pathway and the data sorted by the Enrichment Score
using Fisher’s Exact test.
was analyzed using ArrayStar, to gain insight into their biological
relevance by supervised hierarchical clustering (Figures S2, S3).
This analysis also showed a significant upregulation of S100A12
in bladder cancer patients compared to healthy volunteers. In
addition, the analysis of the different risk groups displayed an
increasing expression pattern of S100A12 among these groups
(Figure 4A). Themost significant upregulation was found among
the high-risk patients with a fold change of 3.15. Among the
intermediate risk patients, the fold change went down to 2.63
and dropped further to only 1.85 among the low risk patients.
Interestingly, in the previously positive group S100A12 also was
found to be upregulated among prognosis group and higher
than what seen in low risk individuals (2.15-fold) (Figure 4A).
Moreover, in the ArrayStar analysis two genes from the S100
family were found to be differentially regulated in UCB patients
compared to healthy volunteers. S100A8 and S100A9 were
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TABLE 4 | Overview of genes differentially regulated in pathway analyses connected to natural killer cells.
Comparison Pathway Gene Up or down regulated
Patient vs. healthy Antigen processing and presentation KIR (Killer-cell immunoglobulin-like receptor) Down
Natural killer cell mediated cytotoxicity NKG2C/E (killer cell lectin-like receptor subfamily C) Down
Intermediate risk vs. healthy Antigen processing and presentation KIR (Killer-cell immunoglobulin-like receptor) Down
Natural killer cell mediated cytotoxicity NKG2C/E (killer cell lectin-like receptor subfamily C) Down
New positive vs. healthy Antigen processing and presentation CD8 (cluster of differentiation 8) Down
Antigen processing and presentation KIR (Killer-cell immunoglobulin-like receptor) Down
Natural killer cell mediated cytotoxicity NKG2C/E (killer cell lectin-like receptor subfamily C) Down
Natural killer cell mediated cytotoxicity NKG2D (killer cell lectin-like receptor subfamily K) Down
Natural killer cell mediated cytotoxicity NKG2DL (killer cell lectin-like receptor subfamily K ligand) Down
Natural killer cell mediated cytotoxicity Perforin Down
New positive vs. previously positive Antigen processing and presentation KIR (Killer-cell immunoglobulin-like receptor) Down
Antigen processing and presentation CD8 (cluster of differentiation 8) Down
Recurrent vs. new positive Natural killer cell mediated cytotoxicity Perforin Up
A pathway analysis was conducted with genes identified as differentially regulated by Partek.
significantly upregulated with a fold change of 1.92 and 1.56,
respectively. Another interesting gene showing a significant
upregulation in the ArrayStar analysis, which had not been found
by Partek software analysis was NAMPT with a fold change
of 2.05.
To validate the microarray analysis results, the expression of
the following selected genes was checked by means of qPCR:
S100A12, S100A8, NAMPT, JUP, KLRF1, and PTGDR. S100A8
was included in this analysis, although this gene did not show
a significant change among all groups in the ArrayStar analysis.
However, it appears in the literature together with S100A12 as
a potential biomarker of bladder cancer in human and dogs
(30, 32, 35). The real-time qPCR was performed using the
housekeeping gene GAPDH as reference. The cDNA samples
were pooled according to their risk and prognostic groups and
the cDNA of each sample was present in equal amount. The
analysis of the risk pools resulted in an expression pattern for
S100A12 similar to ArrayStar analysis and it could be confirmed
that the expression increases with risk (Figure 4B). S100A8 was
shown to be 2-fold upregulated in intermediate risk patients, in
high risk patients the fold change was 1.4 and in the low risk
group it was 1.2. Surprisingly, JUP showed a significant increase
among the high-risk group. Through the prognostic groups, the
expression of S100A12, S100A8, and NAMPT in the new positive
patients is significantly higher than that of previously positive and
recurrent groups (Figure 4C). In contrast, the overexpression
of KLRF1 and PTGDR could not be demonstrated. Considering
this profound microarray expression of S100A12, we screened a
human bladder cancer tissue array using IHCwith an antibody to
S100A12. The tissue array contained, 1 squamous cell carcinoma,
2 adenocarcinoma, 57 cases of urothelial carcinoma, 10 normal
bladder tissue and 10 each of adjacent normal bladder tissue, a
single core per case. S100A12 appears to be mostly expressed in
cells contained within the stroma and not in the tumor tissue.
Necrotic areas showed non-specific staining which was therefore
excluded from the analysis. Figure S4 shows the percentages
of cells that were positive for S100A12 in each tissue sample
group (normal bladder, adjacent normal bladder tissue, T1-3
stage tumors and G1-3 grade tumors). The data shows normal
bladder has the lowest expression of S100A12 and that expression
rises with stage and grade. It is clear that the highest expression
is present in the normal bladder tissue adjacent to the tumor
suggesting immune infiltration by leukocytes (Figure 5).
Plasma S100A12 Concentrations Are
Predictive for UCB
The presence of S100A12 in plasma would indicate that it
could be a potential diagnostic marker, and indeed western
blotting revealed that full-length protein S100A12 could be
detected in the plasma of UCB patients (data not shown).
To quantify the S100A12 concentration in UCB samples,
the S100A12 was analyzed in plasma samples using biolayer
interferometry (BLI). We assessed plasma S100A12 levels in
the same microarray cohort of patients and controls. We
found that S100A12 levels in those diagnosed with UCB were
significantly higher than in healthy volunteers, p < 0.0001.
The mean plasma S100A12 concentration in patients with UCB
was 579.4 ± 30.58 ng/mL, whilst that for control subjects was
311.9 ± 37.03 ng/mL (Figure 6A). For test performance, the
receiver operating characteristic (ROC) area under the curve
(AUC) appeared to be 0.869 with standard error 0.05426 and
p <0.0001, with a sensitivity of 90.5% and a specificity of
75% (see Figure 6B). The ROC analysis study showed that
the ideal cancer-vs.-control plasma concentration threshold of
S100A12 was 350 ng/mL to maximize the test’s sensitivity and
specificity. The 95% confidence interval appeared to be 0.7627–
0.9754. Higher risks and grade tumors (grades 2 and 3) were
connected to highermean plasma S100A12 concentrations (618.3
± 60.59 ng/mL for grade 2 and 562.1± 88.46 ng/mL for grade 3)
than grade 1 tumors (434.5 ± 38.92 ng/mL) (Figure 7A). Area
under the ROC curve for high risk patients against healthy was
0.85 with standard error 0.067, and a 95% confidence interval
of 0.7180 to 0.9820 (Figure 7B). Using an unpaired t-test the
difference in the mean value for high risk vs. healthy was found
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FIGURE 4 | (A) Heat map of S100A12 as most significantly regulated gene in risk groups. The gene and samples are clustered using Centroid linkage and Euclidean
distance metric by ArrayStar software. The diagram row represents the S100A12 gene and the risk groups are presented in the columns. Color saturation reflects the
differences in gene expression between tumor samples; red is higher than control group expression (blue). The intensity of color indicates the degree of gene
expression from red (high expression fold) to yellow (low fold expression). qPCR validation of expression was done for selected genes. Normalized ratio ± ratio error
determined for cDNA pools of study risk (B) and prognostic groups (C) by calculation of the ratio of the samples (target/reference) divided by the ratio of run calibrator
(target/reference) (healthy samples). Quantitative PCR was performed for S100A12 (black), S100A8 (gray), NAMPT (light gray), JUP (red), KLRF1 (blue), and PTGDR
(green). New positive, New UCB cases; recurrent, Cases with recurrence of the disease within 5 years after treatment; previously positive, Cases with UCB history but
negative at the time the sample. ***p ≤ 0.0001 and **p ≤ 0.01.
to be statistically significant (p = 0.047). The best cut-off in
this comparison was found to be 306.9 ng/mL, which gives a
sensitivity of 100% and specificity of 71.43%. The area under the
curve rises when comparing intermediate risk group of cancer
patients to healthy group (Figure 7C). The area under the ROC
curve is 0.888 with standard error 0.052, p < 0.001 and a
95% confidence interval of 0.785 to 0.991. The t-test showed
that difference in the mean value is statistically significant (p
≤ 0.0001). The best cut-off in this contrast was found to be
372.7 ng/mL, which gives a sensitivity of 93.3% and specificity
of 78.5%.
To test if S100A12 can also serve as a recurrence and
prognostic marker, we performed a ROC analysis in the
study prognostics groups. This indicated that the S100A12
concentration could differentiate the UCB-recurrent group and
the previously positive group (recurrent-negative at sample)
from the new positive UCB patients with an area under the curve
of 0.793 and 0.725, respectively (Figures 8A–C). S100A12 also
had diagnostic potential for new UCB patients in this analysis,
with an area under the curve of 0.833 (Figure 8D), a standard
error of 0.065 and p-value of 0.0002. The 95% confidence interval
is 0.704–0.9623. Our results showed that best cut-off can be set to
be 296.9 ng/mL, which gives a sensitivity of 100% and specificity
of 71.43%.
EN2 Lateral Flow Prototype Validation
In this study, we also assessed the performance of the EN2 rapid
test prototype in terms of the sensitivity and specificity of the
test. This lateral flow based rapid test is intended as an in-vitro-
diagnostic test, use of the device is not invasive. All urine samples
are coded by an anonymous sample number. One hundred
and seven coded urine sample, comprising sixty-two patients
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FIGURE 5 | Representative immunohistochemical analysis for tumors of T1, T2, and T3. IHC staining patterns for S100A12 in cancer tissue array tumors stained
withanti-S100A12.
and forty-six healthy samples were used for the test prototypes.
Each urine sample (60 µL) was applied without any dilution to
the test device sample well. Sixty microliters of diluent buffer
was applied after 120 s and the test was left for an additional
20min. Test line intensity was interpreted visually after 15-
and 20-min by comparing the test line to the reference card
(Figure S1). Criterion for re-examination was that no control
line appeared. The results of EN2 rapid tests were compared
with cystoscopic and histological evidence of UCB. In the first
analysis, the clinical specificity and sensitivity were determined
for all positive samples with clinical evidence of bladder cancer
vs. all negative samples from healthy volunteers with no history
of non-bladder cancer, and active cancers (49–56). The results
are summarized in Table 5A. In the second analysis, the clinical
sensitivity of the lateral flow test was determined for tumor
stage and grade using the positive urine specimens confirmed
by means of cystoscopy and histology (62 positive samples). It
was not possible to determine a stage or a grade for only one
specimen. Stage and grade of the tumor, as well as its detection
by the test, are presented in Table 5B. Overall, the sensitivity
of the test was 85.48% (95% CI: 74.22–93.14%) at a specificity
of 71.74% (95% CI: 56.54–84.01%). This result indicated that
the test can potentially distinguish between cancer patients and
healthy individuals.
DISCUSSION
Despite the large and growing list of candidate protein markers
for UCB (5–11), as yet none have entered routine clinical
use. There is no doubt that clinicians need better methods for
individual patients’ treatments and follow-up regimens selection.
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FIGURE 6 | Quantitation of S100A12 in UCB plasma samples by BLI (A). The
concentration of S100A12 was measured from plasma samples of each group
(UCB patients and Healthy) using the biolayer interferometry (BLI). For each
group, the mean value for of S100A12 is shown and standard error of the
mean is represented by error bars. (B) A ROC analysis of plasma S100A12
concentrations in all UCB patients vs. all healthy in study cohort ***p ≤ 0.0001.
It is therefore of paramount importance to recognize novel
and validated UCB biomarkers for the detection of disease its
recurrence. Using microarrays, different studies focused on UCB
global expression profiling (11, 57–61). The main objective of
the current study was identifying biomarkers that will predict the
likelihood of progression in patients with high grade tumors. By
utilizing gene expression profiling, we identified different genes
as a signature biomarker for UCB and tumor progression using
risk and prognostics grouping. In this study, we used a higher
stringency fdr-corrected p-value score cut-off of<0.05 combined
with batch effects removal to minimize any technical sources of
variation (62–64).
Initial comparison was performed on UCB patients using the
healthy group samples as control set. This comparison resulted
in a set of 14 and 141 differentially regulated genes using Partek
and ArrayStar software, respectively. Interestingly, S100A12 is
one of these genes which detected by both software packages
to be upregulated in UCB patients (Figure 2). Further grouping
of the UCB patients based on their prognosis resulted in a
set of 127 differentially regulated genes. Among this multigene
expression signature in UCB blood samples, we can identify
new potential biomarkers for the prognosis of bladder cancer.
KLRF1 encodes the killer cell lectin-like receptor F member
1, which is expressed on human natural killer (NK) cells and
different subsets of T cells (65). It has been shown that a
ligand of this receptor (activation-induced C-type lectin, AICL)
is produced by hematopoetic as well as non-hematopoetic tumor
cells. Blocking of the interaction of AICL and KLRF1 led to a
partial inhibition of NK cell degranulation (65), showing that
these receptors play a key role in the killing of tumor cell by
NK-cells. A differential regulation of this gene in connection
with cancer has not yet been described. Our microarray results
however showed that the expression of this gene in new positive
patients is considerably lower than in recurrent or previously
positive bladder cancer patients. PTGDR is also expressed at
a significantly lower level in new positive patients than in
recurrent and previously positive patients. This gene codes for
the prostaglandin D2 receptor, which is expressed in different
types of cells including immune system cells (NK cells, dendritic
cells) as well as cells of central nervous system and smooth
muscle cells (66). The receptor is activated by prostaglandin D2
which is involved in a variety of different processes like sleep,
regulation of body temperature and release of hormones. It also
inhibits the aggregation of platelets and promotes relaxation
of smooth muscles. It has been shown that the expression of
this gene is downregulated in colorectal adenocarcinomas (67)
and that there is a correlation between this dysregulation and
disease progression as well as a hypermethylation of the gene.
Similar hypermethylation patterns have also been demonstrated
in the case of bladder cancer (68), although expression of the
target gene itself was not been examined. As shown in Table 2
our analysis also revealed other markers in UCB, including
MT-TC (mitochondrial tRNA cysteine), and RNU6-135P (RNA
U6 small nuclear 135). MT-TC has no known role in cancer,
although the expression of tRNA genes in general as well MT-
TC specifically are substantially upregulated in breast cancer
(69). We therefore assumed that downregulation of each of the
four genes or at least three of the four biomarkers, would be
associated with a higher risk of disease recurrence as proposed
for cell cycle regulators (p53, pRB, p21, and p27) (70–72). For
searching expression patterns between UCB samples based on
risk classification the UCB samples were sorted according to
clinical risk score. Our microarray analysis revealed that JUP
was significantly upregulated in samples of high-risk patients
with high grade and stage bladder tumors. This gene encodes
plakoglobin (also known as γ-catenin), which has been reported
to be involved in the reduction of in vitro cell proliferation,
invasion and migration (73) as well as the induction of apoptosis
(74). Rieger-Christ et al. reported that JUP acts as bladder
tumor suppressor and that silencing of this gene in late stage
UCB is associated with tumor progression (75). It has however
Frontiers in Oncology | www.frontiersin.org 11 January 2020 | Volume 9 | Article 1484
Elamin et al. S100A12 and EN2 in Bladder Cancer
FIGURE 7 | A comparison of S100A12 concentrations in plasma within risk groups. (A) Comparison of plasma concentrations of S100A12 in UCB patients divided
into groups according to their risk score. The standard error of the mean is represented by error bars. (B) A ROC analysis of plasma S100A12 concentrations in high
risk UCB patients vs. healthy group. (C) A ROC analysis of plasma S100A12 concentrations of intermediate risk UCB patients against study healthy. ns, not
significant, ***p ≤ 0.0001 and *p ≤ 0.05.
also been demonstrated that wild-type and several mutated
amino-terminal forms of plakoglobin transformed activity on
RK3E epithelial cells (76). Importantly, when we carried out a
pathway analysis for our dataset, the natural killer cell mediated
cytotoxicity pathway appeared to play a major role in the context
of UCB. This is supported by the finding that natural killer
cells are essential for bladder cancer therapy with BCG (Bacillus
Calmette-Guérin), which is frequently administered to treat
superficial tumors (77). In addition, the genes listed in Table 4
have been shown to be important for natural killer cell mediated
cytotoxicity. The receptor NKG2D for example plays a central
role in the recognition of UCB cells by natural killer cells (78).
Here we show a downregulation of this receptor. This could be
due to an interaction with its ligands, which has been shown
previously to downregulate its expression (78). Furthermore, it
has been shown that perforin, which was upregulated in this
analysis, plays an important role in the lysis of UCB cells by
natural killer cells (79).
Characteristics features of the effective biomarkers include
cancer-specific expression and tumor release (15). One gene
group that has been shown to have these properties recently is
the S100 protein family and S100A12 in particular (21, 24, 29,
32, 34, 35), which is expressed in different type of cancers. In our
analysis, S100A12was found to be differentially expressed among
UCB samples and between risk groups. For further analysis,
S100A12 and S100A8 are selected based on the results of the
UCB expression profile. A clear correlation between the qPCR
assays and the microarray data is observed, especially in case of
S100A12 (Figure 4). Both genes were found to be independent
and significant prognostic markers in UCB patients. Our results
also indicated that, as molecular biomarkers, the products of
these genes may be more robust in identifying the high mortality
risk group than others with grade 1 disease, which may need to
be confirmed with further investigations.
It is generally acknowledged that RNA expression level of
a gene does not always reflect the protein expression level,
and thus, in order to investigate the eligibility of S100A12 as
candidate body fluids biomarker, we decided to measure the
concentration of S100A12 in UCB plasma samples and compare
it to healthy group samples. Using the 350 ng/mL as cut off,
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FIGURE 8 | Comparison of S100A12 levels in UCB patient prognostics groups. (A) S100A12 concentrations in plasma from UCB patients sorted according to their
prognosis. The standard error of the mean is represented by error bars. (B) The ROC analysis of plasma S100A12 concentrations of recurrent group against new
positive group of patients. The AUC is 0.793 with standard error 0.09, p = 0.019 and the 95% confidence interval appeared to be 0.6114–0.9759. The best cut-off in
this comparison was found to be 512.5 ng/mL, giving 71.4% sensitivity and 66.67% specificity. (C) A ROC analysis of S100A12 concentration of previously positive
group (recurrent-negative at sample) compared to new positive group. The AUC is 0.725 with standard error 0.095, p = 0.058 and 95% confidence interval between
0.5387 and 0.911. Using the cut-off 462.5 ng/mL the sensitivity is 68.4% and specificity will be 55.56%. (D) ROC analysis of S100A12 of new positive UCB patients
against all healthy. ns, not significant, **p ≤ 0.01 and *p ≤ 0.05.
our data showed that S100A12 has a sensitivity of 90.5% and
a specificity of 75%. The 100% specificity can be achieved
using this assay, with a cut off at 880 ng/mL, the resulting
sensitivity, however, is only 4.8%. The maximum sensitivity
(100%) is obtained with a cut off at 230.4 ng/mL and this
linked with 60% specificity. The cut off value of 350 ng/mL
has been selected to provide high sensitivity and specificity.
S100A12 could also serve as a prognostic biomarker because
our study showed that overexpression of S100A12 protein
was associated with recurrence of the disease as well as with
high-grade/stage tumors (Figures 7, 8). Unexpectedly, our data
also showed that patients with a bladder cancer history, but
negative at the sampling “previously positive” group had elevated
S100A12 compared to healthy subjects. Similar findings were
reported for p53 expression in 692 treated patients with advanced
UCB (70) as well as for Ribonucleotide reductase subunit M1
(RRM1) as a prognostic biomarker (80). S100A12 has been
shown to be secreted from important inflammatory effector cells
such as neutrophils, monocytes, and macrophages (81) and is
recognized as having a significant role in inflammation (24,
27, 30–32, 34, 35, 82, 83). A number of studies reported that
S100A12 ismarkedly expressed in several inflammatory disorders
such as atherosclerosis, inflammatory bowel disease, Kawasaki
disease and coronary artery disease (84). S100B is expressed to
differing degrees in normal tissue such asmelanocytes, astrocytes,
maturing oligodendrocytes, dendritic cells, Langerhans cells,
kidney epithelial cells, and certain lymphocyte subpopulations
(85). Similarly, S100A8/9 were reported to be markers for UCB
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TABLE 5A | EN2 lateral flow test compared by results of clinical diagnosis
(cystoscopy and histology method).
Group Number of
specimens
Clinical sensitivity in %
(95% confidence
interval)
Clinical specificity in %
(95% confidence
interval)
Patients
(cystoscopy
positive or/and
evidence)
(TP/FN)
62
(53/9)
85.48
(74.22–93.14)
71.74
(56.54–84.01)
Healthy (No
history or
evidence)
(TN/FP)
46
(33/13)
Exact Clopper-Pearson confidence intervals were used for sensitivity and specificity.
TP, true positive; FN, false negative; TN, true negative and FP, false positive.
TABLE 5B | Sensitivity of EN2 lateral flow by tumor stage and grade.
Stage of the tumor (I) Number of
specimens
Clinical sensitivity in %
(95% confidence interval)
Ta 35 88.57
(73.26–96.80)
T1 17 94.12
(71.31–99.85)
T2-T3 9 55.56
(21.20–86.30)
Grade of the tumor (II) Number of
specimens
Clinical sensitivity in %
(95% confidence interval)
1 11 90.91
(58.72–99.77)
2 33 87.88
(71.80–96.60)
3 17 76.47
(50.10–93.19)
recurrence and grade, respectively (33). For UCB our data
showed that expression of S100A12 found at the highest level in
normal bladder tissue adjacent to the tumor and at much lower
levels in tumor itself and normal tissue. S100A12 expression are
in line with a previous study in squamous cell carcinoma (86).
This could suggest that the S100A12 signal in bladder may be
due to an immune infiltration by leukocytes such as neutrophils,
monocytes, and macrophages. Further work is needed to be done
to define which cell type is involved in this infiltrate. Although
our samples are limited and S100A12 mRNA has been reported
and linked with UCB (34, 87), to the best of our knowledge, the
current study is the first to indicate an increased level of S100A12
protein and mRNA in human UCB and confirm the association
between S100A12 and progression of UCB. Hence, we propose
the utility of S100A12 at both the mRNA and protein level as a
potential marker for UCB detection and prognosis. In addition,
the relatively small number of samples had somewhat hampered
our data. The current results do not comprise final validation of
the clinical uses of S100A12 in UCB detection and prognosis. We
have initiated further work using an additional validation cohort
to confirm the diagnostic utility of this biomarker.
Additionally, we have previously shown that EN2 is also a
potential diagnostic marker in UCB (15). Rapid lateral flow tests,
although limited, might be more suitable for use due to their
stability, user-friendliness, cost effectiveness, reproducibility, and
rapidness (88). Our attempts to develop a prototype lateral flow
for qualitative detection of EN2 in human urine were very
successful. The sensitivity of the developed test was 85.48% (95%
CI: 74.22–93.14%) at a specificity of 71.74% (95% CI: 56.54–
84.01%). The test sensitivity varies depending on tumor stage and
grade between 55.56 and 94.12% (Table 5B). Thus, the overall
sensitivity and the specificity of the EN2 rapid test reaches or
surpassed the sensitivity and specificity of many bladder cancer
markers and tests on the market (38, 89, 90). These results
may be useful for further development of a highly efficient
non-invasive and improved diagnostic test. The usefulness of
combing S100A12 and EN2 in a single test was assessed using
CombiROC tool. Using a cut off 225 ng/mL as an optimal for
S100A12, the area under curve (AUC) surprisingly rises to 0.93,
and this associated with 92.5% sensitivity and a specificity of
83.1% (Figure S5). This shows that the combination of both
biomarkers may equal or exceed the diagnostic performance of
other promising UCB markers (5, 6, 8–10, 60, 72, 87).
In summary, in this study we examined the gene expression
profile of UCB patients samples and identified several genes
with potential diagnostic value by grouping and comparing
UCB samples according to their clinical risk and prognostics
scores. It is worth noting that these potential markers may
be targets for protein and molecular-based clinical diagnosis
and/or management of UCB. Importantly, our data revealed
a significant increase in the UCB patients in the mRNA and
protein expressions of S100A12. We conclude that S100A12 is an
independent and significant prognostic marker for UCB patients,
which may predict the disease course of UCB patients and
facilitate the clinical management of this cancer. We report here
also EN2 as diagnostic marker and its performance in prototype
rapid lateral flow test assay looks very promising. The prototype
performance encourages us to optimize the current design,
perhaps adding S100A12 to improve sensitivity and specificity.
DATA AVAILABILITY STATEMENT
The datasets generated and analyzed in this study are
available under the following link in the Gene Expression
Omnibus (GEO): https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE138118.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Faculty of Health and Medical Sciences, University
of Surrey local ethical committee (Ref. 3/LO/0739). The
patients/participants provided their written informed consent to
participate in this study.
Frontiers in Oncology | www.frontiersin.org 14 January 2020 | Volume 9 | Article 1484
Elamin et al. S100A12 and EN2 in Bladder Cancer
AUTHOR CONTRIBUTIONS
AE, SKl, SKä, WO, MSt, CS, and GS performed the laboratory
experiments. AE, SKl, RM, HP, and MSi designed the study
and wrote the paper. The final manuscript was reviewed
and approved by all authors. All authors participated in data
collection and analysis.
FUNDING
This work was funded by the Seventh Framework Program of the
European Commission (FP7/ HEALTH.2012.1.2-1) under Grant
Agreement No. 306157 (Project Name: DIPROMON).
ACKNOWLEDGMENTS
We would like to thank individuals in LIONEX GmbH and
DIPROMON project consortium who provided suggestions
or help, and all patients and healthy volunteers involved in
the study.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2019.01484/full#supplementary-material
REFERENCES
1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of
urinary bladder cancer in the world. World J Urol. (2009) 27:289–93.
doi: 10.1007/s00345-009-0383-3
2. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder
cancer: an update. World J Urol. (2019). doi: 10.1007/s00345-019-02984-4.
[Epub ahead of print].
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.
(2010) 60:277–300. doi: 10.3322/caac.20073
4. Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al.
Economic aspects of bladder cancer: what are the benefits and costs?World J
Urol. (2009) 27:295–300. doi: 10.1007/s00345-009-0395-z
5. Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF. Urine-based
biomarkers for the early detection and surveillance of non-muscle invasive
bladder cancer.Minerva Urol Nefrol. (2008) 60:217–35.
6. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and
surveillance of bladder cancer. Can Urol Assoc J. (2008) 2:212–21.
doi: 10.5489/cuaj.600
7. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al.
Urine markers for detection and surveillance of non-muscle-invasive bladder
cancer. Eur Urol. (2011) 60:484–92. doi: 10.1016/j.eururo.2011.05.053
8. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the
evolution of evidence from single studies to meta-analysis, and beyond. Br
J Cancer. (2009) 100:1219–29. doi: 10.1038/sj.bjc.6604999
9. Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers.
Sci World J. (2011) 11:1103–12. doi: 10.1100/tsw.2011.104
10. Horstmann M. Currently available urine-based tumour markers in the
detection of new and recurrent urothelial bladder cancer. Nephrourol Mon.
(2012) 4:345–9. doi: 10.5812/numonthly.1841
11. Miremami J, Kyprianou N. The promise of novel molecular
markers in bladder cancer. Int J Mol Sci. (2014) 15:23897–908.
doi: 10.3390/ijms151223897
12. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in
a high-risk population?: a cost per life-year saved analysis. Cancer. (2006)
107:982–90. doi: 10.1002/cncr.22084
13. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, et al.
Select screening in a specific high-risk population of patients suggests a stage
migration toward detection of non-muscle-invasive bladder cancer. Eur Urol.
(2011) 59:1026–31. doi: 10.1016/j.eururo.2011.03.027
14. Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S,
et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the
early diagnosis of prostate cancer. Clin Cancer Res. (2011) 17:1090–8.
doi: 10.1158/1078-0432.CCR-10-2410
15. Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, et al.
Expression of engrailed-2 (EN2) protein in bladder cancer and its potential
utility as a urinary diagnostic biomarker. Eur J Cancer. (2013) 49:2214–22.
doi: 10.1016/j.ejca.2013.01.019
16. Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, et al.
Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing
radical prostatectomy for prostate cancer. BJU Int. (2012) 110:E287–92.
doi: 10.1111/j.1464-410X.2012.11208.x
17. Punia N, Primon M, Simpson GR, Pandha HS, Morgan R. Membrane
insertion and secretion of the Engrailed-2 (EN2) transcription factor by
prostate cancer cells may induce antiviral activity in the stroma. Sci Rep. (2019)
9:5138. doi: 10.1038/s41598-019-41678-0
18. Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, López-López F,
Herrero-Aguayo V, Hormaechea-Agulla D, et al. Oncogenic role of secreted
engrailed homeobox 2 (EN2) in prostate cancer. J Clin Med. (2019) 8:1400.
doi: 10.3390/jcm8091400
19. Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S, Sauvageau G. EN2 is a
candidate oncogene in human breast cancer. Oncogene. (2005) 24:6890–901.
doi: 10.1038/sj.onc.1208840
20. Konety BR, Getzenberg RH. Urine based markers of urological
malignancy. J Urol. (2001) 165:600–11. doi: 10.1097/00005392-200102000-
00081
21. ChenH, Xu C, Jin Q, Liu Z. S100 protein family in human cancer.Am J Cancer
Res. (2014) 4:89–115.
22. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res
Tech. (2003) 60:540–51. doi: 10.1002/jemt.10296
23. Pietzsch J. S100 proteins in health and disease.Amino Acids. (2011) 41:755–60.
doi: 10.1007/s00726-010-0816-8
24. Pietzsch J, Hoppmann S. Human S100A12: a novel key
player in inflammation? Amino Acids. (2009) 36:381–9.
doi: 10.1007/s00726-008-0097-7
25. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al.
Understanding RAGE, the receptor for advanced glycation end products. J
Mol Med. (2005) 83:876–86. doi: 10.1007/s00109-005-0688-7
26. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious
effects by diverse mechanisms of actions. Mol Cells. (2011) 31:91–7.
doi: 10.1007/s10059-011-0030-x
27. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al.
RAGE mediates a novel proinflammatory axis: a central cell surface
receptor for S100/calgranulin polypeptides. Cell. (1999) 97:889–901.
doi: 10.1016/S0092-8674(00)80801-6
28. Zimmer DB, Eubanks JO, Ramakrishnan D, Criscitiello MF. Evolution of
the S100 family of calcium sensor proteins. Cell Calcium. (2013) 53:170–9.
doi: 10.1016/j.ceca.2012.11.006
29. Bresnick AR,Weber DJ, Zimmer DB. S100 proteins in cancer.Nat Rev Cancer.
(2015) 15:96–109. doi: 10.1038/nrc3893
30. Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng
L. The S100 proteins for screening and prognostic grading of bladder cancer.
Histol Histopathol. (2007) 22:1025–32. doi: 10.14670/HH-22.1025
31. Tondera C, Laube M, Pietzsch J. Insights into binding of S100 proteins
to scavenger receptors: class B scavenger receptor CD36 binds S100A12
with high affinity. Amino Acids. (2016) 49:183–91. doi: 10.1007/s00726-016-
2349-2
32. Yao R, Lopez-Beltran A, Maclennan GT, Montironi R, Eble JN, Cheng L.
Expression of S100 protein family members in the pathogenesis of bladder
tumors. Anticancer Res. (2007) 27:3051–8.
Frontiers in Oncology | www.frontiersin.org 15 January 2020 | Volume 9 | Article 1484
Elamin et al. S100A12 and EN2 in Bladder Cancer
33. Minami S, Sato Y, Matsumoto T, Kageyama T, Kawashima Y, Yoshio K, et al.
Proteomic study of sera from patients with bladder cancer: usefulness of
S100A8 and S100A9 proteins. Cancer Genom Proteom. (2010) 7:181–9.
34. Khorramdelazad H, Bagheri V, Hassanshahi G, Karami H, Moogooei M,
Zeinali M, et al. S100A12 and RAGE expression in human bladder transitional
cell carcinoma: a role for the ligand/RAGE axis in tumor progression? Asian
Pac J Cancer Prev. (2015) 16:2725–9. doi: 10.7314/APJCP.2015.16.7.2725
35. Heilmann RM, Wright ZM, Lanerie DJ, Suchodolski JS, Steiner JM.
Measurement of urinary canine S100A8/A9 and S100A12 concentrations as
candidate biomarkers of lower urinary tract neoplasia in dogs. J Vet Diagn
Invest. (2014) 26:104–12. doi: 10.1177/1040638713516625
36. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-
U, Choi W, et al. Bladder cancer. Lancet. (2016) 388:2796–810.
doi: 10.1016/S0140-6736(16)30512-8
37. Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J,
et al. European association of urology guidelines on non-muscle-invasive
bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. (2019)
76:639–57. doi: 10.1016/j.eururo.2019.08.016
38. Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A. Bladder
cancer: ESMOpractice guidelines for diagnosis, treatment and follow-up.Ann
Oncol. (2014) 25(Suppl. 3):iii40–8. doi: 10.1093/annonc/mdu223
39. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison
of normalization methods for high density oligonucleotide array
data based on variance and bias. Bioinformatics. (2003) 19:185–93.
doi: 10.1093/bioinformatics/19.2.185
40. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries
of Affymetrix GeneChip probe level data. Nucleic Acids Res. (2003) 31:e15.
doi: 10.1093/nar/gng015
41. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model
based background adjustment for oligonucleotide expression arrays. J Am Stat
Assoc. (2004) 99:909–17. doi: 10.1198/016214504000000683
42. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf
U, et al. Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. (2003) 4:249–64.
doi: 10.1093/biostatistics/4.2.249
43. Elamin AA, Stehr M, Oehlmann W, Singh M. The mycolyltransferase 85A, a
putative drug target of Mycobacterium tuberculosis: development of a novel
assay and quantification of glycolipid-status of the mycobacterial cell wall. J
Microbiol Methods. (2009) 79:358–63. doi: 10.1016/j.mimet.2009.10.010
44. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci
M. CombiROC: an interactive web tool for selecting accurate marker
combinations of omics data. Sci Rep. (2017) 7:45477. doi: 10.1038/srep45477
45. Huggins CE, Domenighetti AA, Ritchie ME, Khalil N, Favaloro JM, Proietto J,
et al. Functional andmetabolic remodelling in GLUT4-deficient hearts confers
hyper-responsiveness to substrate intervention. J Mol Cell Cardiol. (2008)
44:270–80. doi: 10.1016/j.yjmcc.2007.11.020
46. Patterson TA, Lobenhofer EK, Fulmer-Smentek SB, Collins PJ, Chu TM, Bao
W, et al. Performance comparison of one-color and two-color platforms
within the MicroArray quality control (MAQC) project. Nat Biotechnol.
(2006) 24:1140–50. doi: 10.1038/nbt1242
47. Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, et al. Transcriptome
analysis of the normal human mammary cell commitment and differentiation
process. Cell Stem Cell. (2008) 3:109–18. doi: 10.1016/j.stem.2008.05.018
48. Kulkarni JN, Bakshi GK. Staging of transitional cell carcinoma: has anything
changed? Ind J Urol. (2008) 24:68–71. doi: 10.4103/0970-1591.38607
49. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ.
(1994) 308:1552.
50. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a
fundamental evaluation tool in clinical medicine. Clin Chem. (1993) 39:561–
77.
51. Davidson M. The interpretation of diagnostic test: a primer
for physiotherapists. Aust J Physiother. (2002) 48:227–32.
doi: 10.1016/S0004-9514(14)60228-2
52. Baratloo A, Hosseini M, Negida A, El Ashal G. Part 1: simple definition and
calculation of accuracy, sensitivity and specificity. Emergency. (2015) 3:48–9.
53. Gardner IA, Greiner M. Receiver-operating characteristic curves and
likelihood ratios: improvements over traditional methods for the evaluation
and application of veterinary clinical pathology tests. Vet Clin Pathol. (2006)
35:8–17. doi: 10.1111/j.1939-165X.2006.tb00082.x
54. Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values
with an emphasis to case-control studies. Stat Med. (2007) 26:2170–83.
doi: 10.1002/sim.2677
55. Hanley JA, McNeil BJ. The meaning and use of the area under a
receiver operating characteristic (ROC) curve. Radiology. (1982) 143:29–36.
doi: 10.1148/radiology.143.1.7063747
56. Clopper CJ, Pearson ES. The use of confidence or fiducial limits
illustrated in the case of the binomial. Biometrika. (1934) 26:404–13.
doi: 10.1093/biomet/26.4.404
57. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining
molecular profiles of poor outcome in patients with invasive bladder
cancer using oligonucleotide microarrays. J Clin Oncol. (2006) 24:778–89.
doi: 10.1200/JCO.2005.03.2375
58. Zaravinos A, Lambrou GI, Volanis D, Delakas D, Spandidos DA. Spotlight
on differentially expressed genes in urinary bladder cancer. PLoS ONE. (2011)
6:e18255. doi: 10.1371/journal.pone.0018255
59. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-
Dutoit S, et al. Identifying distinct classes of bladder carcinoma using
microarrays. Nat Genet. (2003) 33:90–6. doi: 10.1038/ng1061
60. Zaravinos A, LambrouGI, Boulalas I, Delakas D, Spandidos DA. Identification
of common differentially expressed genes in urinary bladder cancer. PLoS
ONE. (2011) 6:e18135. doi: 10.1371/journal.pone.0018135
61. Ying-Hao S, Qing Y, Lin-Hui W, Li G, Rong T, Kang Y, et al.
Monitoring gene expression profile changes in bladder transitional
cell carcinoma using cDNA microarray. Urol Oncol. (2002) 7:207–12.
doi: 10.1016/S1078-1439(02)00192-8
62. McCarthy DJ, Smyth GK. Testing significance relative to a fold-
change threshold is a TREAT. Bioinformatics. (2009) 25:765–71.
doi: 10.1093/bioinformatics/btp053
63. Pusztai L, Hess KR. Clinical trial design for microarray predictive
marker discovery and assessment. Ann Oncol. (2004) 15:1731–7.
doi: 10.1093/annonc/mdh466
64. Luo J, Schumacher M, Scherer A, Sanoudou D, Megherbi D, Davison T,
et al. A comparison of batch effect removal methods for enhancement of
prediction performance using MAQC-II microarray gene expression data.
Pharmacogenomics J. (2010) 10:278–91. doi: 10.1038/tpj.2010.57
65. Akatsuka A, Ito M, Yamauchi C, Ochiai A, Yamamoto K, Matsumoto
N. Tumor cells of non-hematopoietic and hematopoietic origins express
activation-induced C-type lectin, the ligand for killer cell lectin-like receptor
F1. Int Immunol. (2010) 22:783–90. doi: 10.1093/intimm/dxq430
66. Garcia-Solaesa V, Sanz-Lozano C, Padron-Morales J, Hernandez-Hernandez
L, Garcia-Sanchez A, Rivera-ReigadaML, et al. The prostaglandin D2 receptor
(PTGDR) gene in asthma and allergic diseases. Allergol Immunopathol. (2014)
42:64–8. doi: 10.1016/j.aller.2012.12.002
67. Kalmar A, Peterfia B, Hollosi P, Galamb O, Spisak S, Wichmann B, et al.
DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1,
PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer. (2015)
15:736. doi: 10.1186/s12885-015-1687-x
68. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL,
et al. Comprehensive genome methylation analysis in bladder cancer:
identification and validation of novel methylated genes and application
of these as urinary tumor markers. Clin Cancer Res. (2011) 17:5582–92.
doi: 10.1158/1078-0432.CCR-10-2659
69. Pavon-EternodM, Gomes S, Geslain R, Dai Q, RosnerMR, Pan T. tRNA over-
expression in breast cancer and functional consequences. Nucleic Acids Res.
(2009) 37:7268–80. doi: 10.1093/nar/gkp787
70. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ,
et al. p53 expression in patients with advanced urothelial cancer of the
urinary bladder. BJU Int. (2010) 105:489–95. doi: 10.1111/j.1464-410X.2009.
08742.x
71. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet
Y, et al. Combination of multiple molecular markers can improve
prognostication in patients with locally advanced and lymph node
positive bladder cancer. J Urol. (2010) 183:68–75. doi: 10.1016/j.juro.2009.
08.115
Frontiers in Oncology | www.frontiersin.org 16 January 2020 | Volume 9 | Article 1484
Elamin et al. S100A12 and EN2 in Bladder Cancer
72. Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment
selection in advanced bladder cancer patients. Curr Opin Urol. (2011) 21:420–
7. doi: 10.1097/MOU.0b013e32834956d6
73. Aktary Z, Pasdar M. Plakoglobin represses SATB1 expression and decreases
in vitro proliferation, migration and invasion. PLoS ONE. (2013) 8:e78388.
doi: 10.1371/journal.pone.0078388
74. Dusek RL, Godsel LM, Chen F, Strohecker AM, Getsios S, Harmon R,
et al. Plakoglobin deficiency protects keratinocytes from apoptosis. J Invest
Dermatol. (2007) 127:792–801. doi: 10.1038/sj.jid.5700615
75. Rieger-Christ KM, Ng L, Hanley RS, Durrani O, Ma H, Yee AS, et al.
Restoration of plakoglobin expression in bladder carcinoma cell lines
suppresses cell migration and tumorigenic potential. Br J Cancer. (2005)
92:2153–9. doi: 10.1038/sj.bjc.6602651
76. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, et al. Gamma-catenin
is regulated by the APC tumor suppressor and its oncogenic activity is distinct
from that of beta-catenin. Genes Dev. (2000) 14:1319–31.
77. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al.
NK cells are essential for effective BCG immunotherapy. Int J Cancer.
(2001) 92:697–702. doi: 10.1002/1097-0215(20010601)92:5&lt;697::AID-
IJC1245&gt;3.0.CO;2-Z
78. Garcia-Cuesta EM, Lopez-Cobo S, Alvarez-Maestro M, Esteso G, Romera-
Cardenas G, Rey M, et al. NKG2D is a key receptor for recognition of bladder
cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation.
Front Immunol. (2015) 6:284. doi: 10.3389/fimmu.2015.00284
79. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek
C, et al. Perforin-mediated lysis of tumor cells by mycobacterium bovis
bacillus calmette-guerin-activated killer cells. Clin Cancer Res. (2000) 6:
3729–38.
80. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S.
Ribonucleotide reductase subunit M1 expression in resectable, muscle-
invasive urothelial cancer correlates with survival in younger patients. BJU
Int. (2010) 106:1805–11. doi: 10.1111/j.1464-410X.2010.09327.x
81. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Role of
inflammation in the progression of heart failure. Curr Cardiol Rep. (2007)
9:236–41. doi: 10.1007/BF02938356
82. Realegeno S, Kelly-Scumpia KM, Dang AT, Lu J, Teles R, Liu PT, et al.
S100A12 is part of the antimicrobial network against mycobacterium
leprae in human macrophages. PLoS Pathog. (2016) 12:e1005705.
doi: 10.1371/journal.ppat.1005705
83. Kontochristopoulos GJ, Stavropoulos PG, Krasagakis K, Goerdt S, Zouboulis
CC. Differentiation between merkel cell carcinoma and malignant
melanoma: an immunohistochemical study. Dermatology. (2000) 201:123–6.
doi: 10.1159/000018454
84. He YY, Yan W, Liu CL, Li X, Li RJ, Mu Y, et al. Usefulness of S100A12 as a
prognostic biomarker for adverse events in patients with heart failure. Clin
Biochem. (2015) 48:329–33. doi: 10.1016/j.clinbiochem.2014.11.016
85. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-
hand type with intracellular and extracellular functional roles. Int J Biochem
Cell Biol. (2001) 33:637–68. doi: 10.1016/S1357-2725(01)00046-2
86. Funk S, Mark R, Bayo P, Flechtenmacher C, Grabe N, Angel P, et al. High
S100A8 and S100A12 protein expression is a favorable prognostic factor for
survival of oropharyngeal squamous cell carcinoma. Int J Cancer. (2015)
136:2037–46. doi: 10.1002/ijc.29262
87. Lee SJ, Lee EJ, Kim SK, Jeong P, Cho YH, Yun SJ, et al. Identification
of pro-inflammatory cytokines associated with muscle invasive bladder
cancer; the roles of IL-5, IL-20, and IL-28A. PLoS ONE. (2012) 7:e40267.
doi: 10.1371/journal.pone.0040267
88. Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. (2016) 60:111–
20. doi: 10.1042/EBC20150012
89. Abd El Gawad IA,Moussa HS, NasrMI, El Gemae EH,Masooud AM, Ibrahim
IK, et al. Comparative study of NMP-22, telomerase, and BTA in the detection
of bladder cancer. J Egypt Natl Cancer Inst. (2005) 17:193–202.
90. Brown FM. Urine cytology. It is still the gold standard for screening?Urol Clin
North Am. (2000) 27:25–37. doi: 10.1016/S0094-0143(05)70231-7
Conflict of Interest: AE, SKä, WO, MSt, and MSi are employed by LIONEX
GmbH. SKl was employed during DIPROMON project by LIONEX GmbH. For
uses of described biomarkers in this article, AE, SKl, WO, MSt, and MSi have filed
a patent application No.: 16203695.8 and patent No.: 1405 under the title: Novel
Human Bladder cancer Biomarkers and their Diagnostics use.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Elamin, Klunkelfuß, Kämpfer, Oehlmann, Stehr, Smith, Simpson,
Morgan, Pandha and Singh. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Oncology | www.frontiersin.org 17 January 2020 | Volume 9 | Article 1484
